LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the ...
Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in a new awareness campaign. The project kicked off Friday, World Diabetes Day ...
Dexcom has issued a Class I recall for its G6 glucose sensor Android application due to a defect that causes the app to crash unexpectedly. As a result of the app terminating, users could miss ...
Ladies and gentlemen, welcome to the DexCom Third Quarter 2025 Earnings Release Conference Call. My name is Abby, and I will be your operator for today's call. [Operator Instructions] As a reminder, ...
Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after market close. Here’s what you need to know. DexCom beat analysts’ revenue expectations by 2.8% last quarter, ...
DexCom, Inc. DXCM reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in expanding access and meaningful product innovation. Revenues grew 15% year over ...
Dexcom has recalled its G6, G7, ONE, and ONE+ continuous glucose monitor (CGM)receivers due to a speaker malfunction that could cause missed low or high blood sugar alerts. The recall, for which ...
Shares of DexCom Inc. DXCM slipped 2.81% to $84.89 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.61% to 5,844.61 and ...
In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...
Shares of DexCom Inc. DXCM slipped 1.72% to $66.14 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.81% to 5,363.36 and the ...
The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users. Taylor Leamey wrote about all things wellness for CNET, specializing in ...
The Dexcom 15-day G7 continuous glucose monitor (CGM) is accurate and safe for use up to 15.5 days in adults with diabetes. Currently under review by the US Food and Drug Administration, it is more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback